Please login to the form below

Not currently logged in

immune disease

This page shows the latest immune disease news and features for those working in and with pharma, biotech and healthcare.

J&J splashes $750m on anti-inflammatory drug bermekimab

J&J splashes $750m on anti-inflammatory drug bermekimab

Janssen is a world leader in immunology, and we are particularly proud of our long legacy of helping patients with dermatological disease, including psoriasis,” said David M. ... Lee, immunology therapeutic area head, Janssen Research &Development.

Latest news

More from news
Approximately 1 fully matching, plus 55 partially matching documents found.

Latest Intelligence

  • Biotech profile: Tom Evans, CEO, Vaccitech.

    Vaccitech’s platform, which induces the cellular side of the immune system against disease targets, could be one approach in which a more powerful and durable T cell response is required.

  • Case study: Ask for Clear Case study: Ask for Clear

    Psoriasis is an auto-immune disease that affects 2.8% of the UK population and 125 million people worldwide.

  • Pharma deals in July 2015 Pharma deals in July 2015

    cCAM is developing an immune checkpoint protein belonging to the Human CEA (Carcino-Embryonic Antigen) protein family. ... Receptos / Celgene. Company acquisition. Ozanimod in Phase 3 for auto-immune disease.

  • Deal Watch table for May 2014 Deal Watch table for May 2014

    658. Avalanche / Regeneron. Development and commercialisation licence. Gene therapy products for ophthalmologic disease. ... MGD010, a preclinical bispecific antibody for treatment of auto-immune disease. 502.

  • Interview: AstraZeneca's Susan Galbraith Interview: AstraZeneca's Susan Galbraith

    Immuno-oncology. One area of interest for many pharma companies is the potential for immunotherapies - drugs that encourage the body's immune system to tackle a disease. ... or with other agents that might affect a different part of the immune system, or

More from intelligence
Approximately 0 fully matching, plus 5 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest from PMHub

  • UK vs US: what makes a successful immunisation programme?

    The success of infectious disease control depends in part on the strength of national immunisation programmes, which aim to achieve herd immunity – 95% of the population are immune to a contagious ... disease. When herd immunity is achieved, it is very

  • Body image and mental health: The psoriasis connection

    Psoriasis is an inflammatory, auto-immune skin disease, which causes the skin to grow many times faster than normal. ... 4. however the two largest contributors are the belief they are being judged on the basis of their skin disease and engaging in

  • Australian Flu and the dilemma of naming diseases

    as disease carriers, and creating negative connections between the name and the country. ... Other examples include the damaging 1980s media branding of AIDS disease as GRID (gay-related immune deficiency) and the immense impact on local tourism for

  • Random42 Proud To Be Cannes Corporate Award Winners 2016

    Silver Winner - Random 42 for Systematic Lupus Erythematosus. This animation highlights the pathogenesis of Lupus, an autoimmune disease where the body’s own immune system attacks healthy tissue. This animation was

  • Driving Earlier Diagnosis: A Case Study in Psoriatic Arthritis

    market. PsA is an auto-immune disease which causes inflammation of the joints, pain and stiffness, which is accompanied by patches of red and white, scaly skin indicative of Psoriasis.PsA ... The exact causes of the disease are not yet known, but a

More from PMHub
Approximately 0 fully matching, plus 5 partially matching documents found.

Featured jobs

Subscribe to our email news alerts


Add my company
mXm Medical Communications

mXm Medical Communications meets the needs of pharmaceutical marketers and medics who require a highly experienced, bespoke service from their...

Latest intelligence

David Atkins
A snapshot of Congenica
PME talks to CEO David Atkins...
Data desires
What are you looking to achieve with data and how are you preparing yourself to react to the results?...
The balancing act that’s keeping pharma and biotech market access on its toes
Pricing drugs and gaining reimbursement can be a real challenge for drug developers. Price it too high, and no one buys it. Price it too low, and it’s hard to...